NCT06843707Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.
Source: ClinicalTrials.gov · Last updated 25 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 12 Jan 2025
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer
- NCT number
- NCT06843707
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 1 Jan 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with obstructive lesions such as airway or esophageal stenosis;
- (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Other illness
- Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
Other
- Poor preoperative pulmonary function cooperation or missing reports;
- Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
- The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
- Coexisting with other severe functional impairments;
Who the study is looking for
- Signing of the informed consent form;
- Male or female, aged 18-75 years;
- Patients with lung nodules confirmed by CT examination;
- Good preoperative pulmonary function cooperation and complete reporting;
- Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
- The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the First Affiliated of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.